Adapted fencing program to help hematology patients stay active
Feasibility of an Adapted Sports Program Based on Fencing to Reduce Physical Deconditioning in Adult Hematology Patients Receiving Intensive Treatment
This study is testing whether an adapted fencing program can help adults with acute leukemia stay active and improve their quality of life during intensive treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Angers Government |
| Drugs / interventions | CAR-T, chemotherapy |
| Locations | 2 sites (Angers and 1 other locations) |
| Trial ID | NCT06026046 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility of an adapted sports program based on fencing to combat physical deconditioning in adult patients with acute leukemia undergoing intensive treatment. The program aims to initiate physical support early in the treatment process, addressing the complications associated with prolonged hospitalization and room confinement. By engaging patients in a structured physical activity, the study seeks to improve treatment response, tolerance, quality of life, and long-term survival outcomes. The intervention will be conducted in protected units of participating hematology departments.
Who should consider this trial
Good fit: Ideal candidates include adult patients with acute leukemia who are undergoing intensive chemotherapy and require prolonged hospitalization.
Not a fit: Patients with neurological or cardiac diseases that contraindicate fencing, or those not undergoing intensive treatment, may not benefit from this program.
Why it matters
Potential benefit: If successful, this program could significantly enhance the physical well-being and overall quality of life for hematology patients undergoing intensive treatments.
How similar studies have performed: Previous studies have shown the feasibility and benefits of physical support for hematology patients, although few have focused on early intervention at the diagnosis of acute leukemia.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient admitted to a protected unit of the Hematology department of one of the participating centers * Patient with acute leukemia treated in induction with "3+7" or "5+7" intensive treatment or by an equivalent treatment (Vyxeos, azacitidine+vénetoclax), or patient admitted for an allograft or CAR-T cells and not included at the diagnosis of the disease * Patient eligible for intensive chemotherapy * Patient requiring prolonged hospitalization with room confinement * Signed informed consent form Exclusion Criteria: * Patient with a neurological or cardiac disease that contraindicates the practice of fencing * No intensive treatment with prolonged hospitalization * Pregnant, parturient or breastfeeding woman * Person deprived of liberty by judicial or administrative decision * Person under forced psychiatric care * Person under legal protection * Person unable to express consent * Person not covered by or not benefiting from a social security system
Where this trial is running
Angers and 1 other locations
- University Hospital, Angers — Angers, France (Recruiting)
- University Brest Hopspital — Brest, France (Suspended)
Study contacts
- Principal investigator: Aline MD Schmidt, PHD — University Hospital, Angers
- Study coordinator: Aline MD Schmidt, PHD
- Email: aline.schmidt@chu-angers.fr
- Phone: 02 41 35 36 37
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.